Petros Pharma: Rises as mid-stage study begins for erectile dysfunction drug

Petros Pharmaceuticals

13/07/2021 18:23

** Shares of men's health co  PTPI.O  up 1.8% at $3.14 in
afternoon trade 
    ** Co completes pilot study, the first step to obtain
over-the-counter (OTC) status from the FDA for its erectile
dysfunction medication, Stendra  urn:newsml:reuters.com:*:nPn6vj6qza
    ** Co has initiated a Phase 2 study, which may be considered
the pivotal study to continue toward an application for OTC
designation
    ** "If approved for OTC status by the FDA, Stendra would be
among the first oral ED therapies to gain such a designation" -
PTPI chief commercial officer
    ** It is estimated that over 30 mln men in the U.S. suffer
from erectile dysfunction 
    ** Stock down 28% YTD 

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))